[ad_1]
More than 50 countries bid for more than 1.2 billion doses of Sputnik V vaccine
During the tests of the Russian vaccine, 20 people were infected with the coronavirus, but it will still be produced.
According to the results of the first interim analysis of the third phase of clinical trials of the drug in Russia, the effectiveness of the vaccine against the coronavirus COVID-19 Sputnik V was 92%. This was announced by the Russian Direct Investment Fund (RDIF) on Wednesday, November 11.
“The study evaluated the efficacy of more than 16,000 volunteers 21 days after receiving the first dose of vaccine or placebo. The statistical analysis included 20 confirmed cases. By distribution of 20 confirmed cases (identified in the placebo group and in the group of vaccine) it was determined that the efficiency of Sputnik V was 92% “, – said in the message.
It is also observed that the observation of 10,000 vaccinated among additional volunteers outside the clinical trials of doctors and other risk groups confirmed the effectiveness of the vaccine at a level of more than 90%.
The message indicates that the data obtained will be published by the NNNF Gamalei team in one of the world’s leading peer-reviewed scientific medical publications after independent evaluation by leading international experts in the field of epidemiology.
Until November 11, in the course of clinical trials in Russia on the basis of 29 medical centers, more than 20,000 volunteers were vaccinated with the first dose of the vaccine and more than 16,000 volunteers with the first and second doses of the vaccine. During the study, no unexpected adverse events were identified. Some of those vaccinated had short-term adverse events, such as injection site pain, flu-like syndrome, including fever, weakness, fatigue, and headache.
Follow-up of study participants will continue for six months, after which a final report will be prepared. Currently, the third phase of clinical trials in Belarus, the United Arab Emirates, Venezuela and several other countries, as well as the second and third phases in India, have also been approved and are underway. Also in the Russian Federation, a separate clinical study of the safety and immunogenicity of the vaccine is being carried out with the participation of older people.
According to Russian Health Minister Mikhail Murashko, whose words are quoted in the message, the results of clinical studies of the Sputnik V vaccine show that it is an effective means of stopping the spread of COVID-19.
To date, more than 50 countries have received offers for more than 1.2 billion doses of the Sputnik V vaccine. The vaccine for supply to foreign markets will be produced by RDIF’s international partners in India, Brazil, China, Korea and others. countries.
Recall that on August 11, Russian President Vladimir Putin announced that Russia became the first country in the world to register a vaccine against the coronavirus. Later it was called Sputnik V.
The vaccine has been criticized by various sources. For example, the United States criticized the insufficient testing of the Russian vaccine, while Germany expressed doubts about its safety.
In turn, Russia has already launched Sputnik V into civilian circulation. It will be delivered to all regions of the country.
News of Correspondent.net on Telegram. Subscribe to our channel https://t.me/korrespondentnet
